The Clinical Pharmacogenetics Implementation Consortium Guideline offers treatment recommendations for aminoglycoside use based on MT-RNR1 genotypes, suggesting alternatives unless the severity of infection outweighs the high risk of permanent hearing loss and no safe or effective alternatives are available [35]. Here, NR4A2 is linked to infection.